4 I SEED WORLD EUROPE I SEEDWORLD.COM/EUROPE | OCTOBER 2026 EDITOR’S MESSAGE EUROPE’S 20-NUCLEOTIDE HANDBRAKE BY: MARCEL BRUINS E urope has finally moved on New Genomic Techniques (NGTs), and for that the seed sector should allow itself a moment of cautious celebration. After years of legal uncertainty, political wrangling and the long shadow of the GMO debate, the EU is preparing to create a dedicated framework for plants obtained through targeted mutagenesis and cisgenesis. That is no small thing. For plant breed ers, it means that not every gene-edited plant will automatically be pushed into the full machinery of GMO legislation. Some NGT plants will be recognised as suffi ciently equivalent to conventionally bred plants and will follow a lighter route. Yet the celebration comes with a familiar European footnote. The door has opened, but someone in Brussels is standing beside it with a ruler. At the heart of the regulation is a two-category system. Category 1 NGT plants are those considered equivalent to plants that could occur naturally or be obtained through conventional breed ing. These plants will not be regulated as GMOs, although they will still require verification. Category 2 covers the rest: NGT plants that fall outside the Category 1 criteria and therefore remain subject to GMO-style authorisation, risk assessment, labelling, traceability. The trouble is that the fast lane may be rather narrow. One of the most discussed limits is the famous, or perhaps infamous, 20-nucleo tide threshold. Under the Category 1 cri teria, certain substitutions or insertions may involve no more than 20 nucleotides. There are also limits on the number of modifications. Deletions are treated differ ently and can be larger, which gives breed ers some useful room for gene knockouts and gene silencing. But for insertions and substitutions, the 20-nucleotide bound ary has become the symbolic fence around European comfort. This is where the regulation starts to look less like a scientific tool and more like a policy compromise wearing a lab coat. Twenty nucleotides may sound precise, but precision is not the same as wisdom. Plant genomes are not tidy filing cabinets where disruption can be predicted solely by measuring the length of an edit. A small change can have a large effect. Natural variation, conventional mutagenesis and ordinary breeding can produce genetic differences far beyond what this threshold appears willing to tolerate. From a breeding perspective, that is the frustration. The problem is that it has created a Category 1 route and then surrounded it with restrictions that may exclude useful, safe and urgently needed innovations. The herbicide tolerance exclusion is another example. It simply moves the plant out of Category 1. The same applies to traits involving the production of a known insecticidal substance. This is why some critics from the innovation side say Europe is still working with one hand tied behind its back. The new framework may allow many SDN1-type outcomes, where a small targeted mutation is introduced without adding new genetic material. But more precise sequence changes associated with SDN2, and larger insertions associated with SDN3, are far more likely to fall into Category 2. For readers allergic to gene-editing alphabet soup, SDN1, SDN2 and SDN3 are best understood as different levels of editing. SDN1 is like making a small, targeted change. SDN2 can make a more directed correction or replacement using a repair template. SDN3 can introduce larger pieces of genetic material. The future of plant breeding will not only be about making tiny changes. Breeders will need a wide toolbox to develop varieties that can cope with heat, drought, salinity, emerging pests, changing disease pressure, reduced inputs and shift ing consumer expectations. Some valuable traits will fit neatly within Category 1. Others will not. But policy should not rely on breeders being forced to perform regulatory gymnas tics. The purpose of modernising the law should be to enable responsible innovation, not to reward only those innovations that can squeeze through a molecular keyhole. The irony is that the EU itself rec ognises the central scientific point. Some NGT changes are indistinguishable from changes that could arise naturally or through conventional breeding. Yet having accepted that principle, the regulation then becomes nervous and starts counting nucle otides as if plant breeding were a game of regulatory Jenga. Pull out the right 20 pieces, and everything is fine. Add one too many, and the tower must be inspected under GMO rules. The seed sector can welcome the mile stone and still criticise the handbrake. The 20-nucleotide threshold may have been designed as a reassurance mechanism. But reassurance has a cost when it becomes over-engineered. If the threshold excludes too many useful innovations, it will not merely classify technologies. Europe has taken an important step. It has been recognised that not all gene-edited plants should be treated like classical GMOs. But by building a fast lane with a 20-nucle otide speed bump, trait exclusions, and a lingering fear of broader precision breeding, Europe may still be doing what it has done too often in agricultural innovation: moving forward while pressing the brake. For plant breeders, the message is therefore mixed. Welcome to the future, but please keep your edits short. Marcel Bruins editorial director, Seed World Europe mbruins@seedworldgroup.com This column is an abbreviated version of an article previously published on Seed World Europe. For the full version, scan the QR code.
View this content as a flipbook by clicking here.